REVIEW ARTICLE


Role of Glucagon-like Peptide-1 (GLP-1) Agonists in the Management of Diabetic Patients with or without COVID-19



Fatemeh Mirzaei1, 2, Iraj Khodadadi3, Nesrine Majdoub4, Seyyed Alireza Vafaei1, Heidar Tayebinia3, Ebrahim Abbasi1, 3, *
1 Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
2 Department of Anatomy, School of medicine, Hamadan University of Medical Sciences, Hamadan, Iran
3 Department of Clinical Biochemistry, Hamadan University of Medical Sciences, Hamadan, Iran
4 Faculdade de Ciências e Tecnologia, MeditBio, Universidade do Algarve, Campus de Gambelas, 8005-139 Faro, Portugal


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 291
Abstract HTML Views: 68
PDF Downloads: 135
ePub Downloads: 60
Total Views/Downloads: 554
Unique Statistics:

Full-Text HTML Views: 156
Abstract HTML Views: 59
PDF Downloads: 83
ePub Downloads: 53
Total Views/Downloads: 351



Creative Commons License
© 2022 Mirzaei et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at Department of Clinical Biochemistry, Faculty of Medicine, Hamadan University of Medical Sciences, Shahid Fahmideh Street, Hamadan, Iran; E-mail: 7abbasi@gmail.com, a.oshaghi@umsha.ac.ir


Abstract

Glucagon-like peptide 1 (GLP-1) is a gut-derived hormone released after a meal, which alleviates hyperglycemia, increases β-cell survival, reduces body weight, and reduces inflammation. These thrilling effects motivated clinical studies to discover the potential use of GLP-1 receptor agonists (GLP-1 RAs) in the management of T2D. GLP-1 RAs are potential anti-diabetic agents that can reduce blood pressure, glucose levels, HbA1c and, weight loss without hypoglycemia risk. This manuscript reviews the importance of GLP-1 RAs‎ and their role in the management of T2D with or without COVID-19 infection. Hence, this manuscript can help physicians and researchers to choose the most appropriate drugs for the individualized treatment of subjects.

Keywords: COVID-19, Coronavirus, GLP-1R agonist, Glucagon-like peptide-1, Incretin.